Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Registration Number
- NCT02177318
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3588
Inclusion Criteria
- Patients with COPD
Exclusion Criteria
-There is no exclusion criterion, because this post marketing study (PMS) is observational survey under condition of normal clinical practice
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with COPD Spiriva (tiotropium bromide) inhalation capsules -
- Primary Outcome Measures
Name Time Method Number of patients with adverse events Up to 4 weeks after start of treatment Number of patients with adverse drug reactions Up to 4 weeks after start of treatment Number of patients with serious adverse events Up to 4 weeks after start of treatment
- Secondary Outcome Measures
Name Time Method Physician's overall judgement by medical interview into four grades: 1. Improved 2. No Change 3. Aggravated 4.Unassessable Up to 4 weeks after start of treatment
Trial Locations
- Locations (1)
Boehringer Ingelheim Investigational Site
🇯🇵Yurihonjou, Japan